A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Affiliations

¹ Dept. of Hematology, St Vincent's Hospital, University of Melbourne,. hang.quach@svha.org.au.
² Illawarra Cancer Care Centre, Wollongong, NSW, Australia.
³ Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
⁴ Molecular Oncology and Cancer Immunology, Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia.
⁵ Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
⁶ Department of Hematology, Blacktown and Mount Druitt Hospitals, Blacktown, NSW, Australia.
⁷ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
⁸ Early Phase Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
⁹ MD Anderson Cancer Center, Gilbert, AZ.
¹⁰ Department of Hematology, City of Hope National Medical Center, Duarte, CA.
¹¹ Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
¹² Sanofi, Research and Development, Cambridge, MA.
¹³ Sanofi, Research and Development, Reading.
¹⁴ Sanofi, Research and Development, Vitry-sur-Seine.
¹⁵ Department of Hematology, University Hospital of Nantes, Nantes, France.

Hang Quach et al. Haematologica. 2024.

. 2024 Dec 1;109(12):4078-4082.

doi: 10.3324/haematol.2023.284730.

¹ Dept. of Hematology, St Vincent's Hospital, University of Melbourne,. hang.quach@svha.org.au.
² Illawarra Cancer Care Centre, Wollongong, NSW, Australia.
³ Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
⁴ Molecular Oncology and Cancer Immunology, Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia.
⁵ Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
⁶ Department of Hematology, Blacktown and Mount Druitt Hospitals, Blacktown, NSW, Australia.
⁷ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
⁸ Early Phase Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
⁹ MD Anderson Cancer Center, Gilbert, AZ.
¹⁰ Department of Hematology, City of Hope National Medical Center, Duarte, CA.
¹¹ Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
¹² Sanofi, Research and Development, Cambridge, MA.
¹³ Sanofi, Research and Development, Reading.
¹⁴ Sanofi, Research and Development, Vitry-sur-Seine.
¹⁵ Department of Hematology, University Hospital of Nantes, Nantes, France.

No abstract available

References

1. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464-477. - PubMed
1. Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425-440. - PMC - PubMed
1. National Comprehensive Cancer Network. NCCN Guidelines, Multiple Myeloma. Version 4.2024. https://www.nccn.org. Accessed August 27, 2024.
1. McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. Pharmacoecon Open. 2023;7(1):3-36. - PMC - PubMed
1. O’Shaughnessy J, Sousa S, Cruz J, et al. PHranceSCa study group. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223-232. - PubMed